Key Findings
U.S. radiopharmaceutical company NorthStar Medical Technologies has made a groundbreaking stride in the therapeutic radioisotope market. In January 2026, the company became the first in the industry to achieve commercial-scale production of carrier-free Actinium-225 (Ac-225) using electron accelerator technology, significantly enhancing its radiopharmaceutical manufacturing capacity. Furthermore, in April 2026, the U.S. Food and Drug Administration (FDA) accepted NorthStar’s Type II Drug Master File (DMF) for its isotopes. This crucial regulatory milestone allows pharmaceutical sponsors to directly reference NorthStar’s manufacturing data in their Investigational New Drug (IND) and New Drug Application (NDA) submissions, streamlining the drug development process.
Technical and Clinical Details
- Commercial Production of Carrier-Free Ac-225: Ac-225, an alpha-emitting radionuclide, is a critical component for targeted radiotherapies (TRTs), valued for its potent ability to destroy cancer cells. NorthStar’s innovative approach utilizes electron accelerator technology to produce carrier-free Ac-225 from Rubidium-82 rather than Uranium-238. This methodology offers a cleaner, more scalable supply route compared to traditional reactor-based production, reducing impurity risks.
- Copper-67 (Cu-67) Manufacturing: In addition to Ac-225, NorthStar also manufactures Copper-67 (Cu-67), which serves as a linker for both diagnostic and therapeutic radiopharmaceuticals. This dual capability positions NorthStar as a key supplier of essential radioisotopes for targeted radiopharmaceutical development.
- FDA Type II DMF Acceptance: A Type II DMF contains detailed, confidential information about the facilities, processes, packing, and storage used in the manufacturing of a drug substance, reviewed by the FDA. Its acceptance means that drug developers can simply reference this DMF in their regulatory applications, avoiding the need to submit extensive manufacturing details independently, thereby accelerating the approval pathway.
Background and Context
Radiopharmaceuticals, particularly alpha-emitting radionuclides, hold immense promise as innovative treatments for various solid and hematologic cancers. However, a longstanding challenge has been the unstable and limited supply of key radioisotopes like Ac-225. NorthStar’s commercial production via electron accelerator technology addresses this supply constraint, enabling the development of more therapeutic agents. The FDA’s DMF acceptance further validates the quality and regulatory compliance of NorthStar’s manufacturing processes, easing access for the broader pharmaceutical industry.Strategic Significance and Outlook
NorthStar Medical Technologies’ announcement signifies a pivotal moment for the radiopharmaceutical market. The stable supply of high-quality Ac-225 and Cu-67 is expected to accelerate the research, development, and commercialization of targeted radiotherapies for cancer. This will ultimately increase the availability of effective new treatments for patients with previously limited therapeutic options. The company’s CDMO (Contract Development and Manufacturing Organization) capabilities and proprietary technology are poised to be foundational pillars supporting the growth of the entire radiopharmaceutical ecosystem.
Source: https://www.thepharmaletter.com/ones-to-watch/northstar-medical-technologies
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
